Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2975
Journal of Clinical & Experimental Pathology received 2975 citations as per Google Scholar report
Journal of Clinical & Experimental Pathology peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- Cosmos IF
- Ulrich's Periodicals Directory
- RefSeek
- Directory of Research Journal Indexing (DRJI)
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
- world cat
- journal seek genamics
- j-gate
- esji (eurasian scientific journal index)
Useful Links
Recommended Journals
Related Subjects
Share This Page
Association of MDR1 gene polymorphism (G2677T) with Imatinib response in Egyptian chronic myeloid leukemia patients
9th World Digital Pathology & Pathologists Congress
Lamia Ibrahim
Mansoura University, Egypt
Posters & Accepted Abstracts: J Clin Exp Pathol
Abstract
Background: Despite the excellent efficacy results of imatinib treatment in CML patients, resistance to imatinib has emerged as a significant problem. Genetic variations in genes involved in drug transportation might influence the pharmacokinetic and metabolism of imatinib. The genotype of a patient is increasingly recognized in influencing the response to the treatment. Aim: To investigate the genotype frequencies of single nucleotide polymorphisms (SNPs) G2677T in CML patients undergoing imatinib treatment to determine whether different genotype pattern of these SNPs have any influence in mediating response to imatinib. Methods: A total of 96 CML and 90 control samples were analyzed for the human multidrug resistance gene 1 (MDR1) gene polymorphism (G2677T) using polymerase chain reaction-restriction fragment length polymorphism technique. Results: Genotype distribution revealed a significant lower frequency of TT genotype in CML patients and nonsignificant difference in the GG, GT genotype frequencies between patients and controls (P=0.004, 0.138, 0.210, respectively). GG genotype was significantly higher in chronic phase (P=0.046), while GT genotype was significantly higher in Blastic crisis phase (P=0.002). There was a significant difference in genotype frequency of G2677T among patients showing response and resistance to imatinib in chronic phase (P=0.02). TT genotype was associated with complete hematological response (P=0.01), complete cytogenetic response (P<0.001), and better molecular response with a significant association (P<0.001). GT genotype was associated with partial hematological response (P=0.01) and minor cytogenetic response (P<0.001). Optimal and suboptimal responses were observed for patients with TT genotype (P=0.003). Failure of drug response was associated with GT genotype (P=0.02); however, GG had no association with drug response. Multivariate analysis considered GT genotype as independent risk factor for resistance (P=0.037), while TT genotype as protective factor against resistance to imatinib (P= 0.008). Conclusion: Determination of MDR1 polymorphisms (G2677T) might be useful in response prediction to therapy with imatinib in patients with CML.Biography
Email: Loomy16@yahoo.com
